2 results
Approved WMORecruiting
-To investigate whether a short-term treatment (3 months) with benfotiamine in diabetic nephropathy patients leads to a reduction in urinary excretion of β2-microglobulin and albumin.-To investigate whether short-term treatment (3 months) with…
Approved WMORecruiting
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…